dx 8951

MC-GGFG-DX8951 (MC-GGFG-Exatecan) is an antibody-coupled drug (ADC) drug-linker conjugate (DLC) consisting of DX8951, a potent DNA topoisomerase I inhibitor, the linker MC, and the cleavable peptide chain GGFG, and has antitumor potential.

DBCO-PEG4-GGFG-DX8951 is a click-reactive Drug-linker that contains a DBCO group and can undergo a strain-promoted acetylene-nitride cycloaddition reaction (SPAAC) with molecules containing an Azide group. DX8951 is a DNA topoisomerase I (topoisomerase I) inhibitor. DBCO-PEG4-GGFG-DX8951 can be used in the synthesis of antibody-drug conjugates (ADCs).

Py-MAA-Val-Cit-PAB-DX8951, a purine toxin, serves as an intermediate in the synthesis of antibody-drug conjugates [1].

Exatecan (DX-8951f) is a DNA topoisomerase I (TOP1) inhibitor with an IC50 value of 2.2 μM (0.975 μg/mL).Exatecan has antitumor activity and may be used in cancer research.

Mal-Exatecan (Mal-DX-8951) is a malonamide (Mal)-modified antibody-drug conjugate used for preparing ADCs (antibody-drug conjugates) and studying cancer. Exatecan is an effective topoisomerase I inhibitor

MC-Val-Cit-PAB-Exatecan (MC-Val-Cit-PAB-DX8951) consists of a cytotoxin, the topoisomerase I inhibitor DX-8951, and a linker sensitive to cathepsin, forming a drug-linker conjugate for antibody-drug conjugates (ADCs).

Val-Cit-PAB-Exatecan TFA (Val-Cit-PAB-DX8951 TFA) forms part of an antibody-drug conjugate (ADC). The compound consists of the DNA topoisomerase I inhibitor DX-8951 and a protease-degradable ADC linker.

Glycyl-Exatecan TFA (Glycyl-DX-8951 TFA) is a derivative of Exatecan and serves as an anticancer agent. It exhibits significant antitumor activity and can be utilized in research related to cancer, such as solid tumors.

Ac-Exatecan (Ac-DX-8951) is acetylation-modified Exatecan.Exatecan (DX-8951) is a DNA topoisomerase I (TOP1) inhibitor with an IC50 value of 2.2 μM and antitumor activity.

Exatecan mesylate dihydrate (DX-8951), a DNA topoisomerase I inhibitor, exhibits an IC50 of 2.2 μM (0.975 μg/mL) and is utilized in cancer research [1] [2] [3].

Exatecan Mesylate (DX8951f) is a DNA topoisomerase I inhibitor (IC50: 2.2 μM, 0.975 μg/mL).

Deruxtecan is an ADC drug-linker conjugate composed of a derivative of DX-8951 (DXd) and a maleimide-GGFG peptide linker used in the synthesis of DS-8201 and U3-1402.

Exatecanintermediate 8 serves as an intermediate in the synthesis of Exatecan. Exatecan (DX-8951) is a commonly used cytotoxin component in ADC (Antibody-Drug Conjugate) preparation, and it functions as an inhibitor of DNA topoisomerase I (IC50=2.2 μM).

Exatecanintermediate 10 serves as an intermediate in synthesizing Exatecan. Exatecan (DX-8951) is a DNA topoisomerase I inhibitor with an IC50 value of 2.2 μM (0.975 μg/mL), utilized for cancer research.

Exatecan Intermediate 3 is an intermediate of Exatecan. Exatecan (DX-8951) is a DNA topoisomerase I inhibitor with an IC50 value of 2.2 μM (0.975 μg/mL), and it is utilized in cancer research. Exatecan Intermediate 3 can be employed in the synthesis of Antibody-Drug Conjugates (ADCs).

Exatecanintermediate 11 is an intermediate compound used in the synthesis of Exatecan. Exatecan (DX-8951) is a frequently utilized cytotoxic component in the preparation of antibody-drug conjugates (ADC Cytotoxin) and serves as an inhibitor of DNA topoisomerase I (topoisomeraseI) with an IC50 of 2.2 μM.

Antitumor agent-203 (compound 26) is a derivative of Exatecan (DX-8951) and serves as an ADC cytotoxin for antibody-drug conjugate (ADC) preparation.

Deruxtecan analog 2 (monoTFA), a homolog of Deruxtecan, consists of the antibody-drug conjugate (ADC) toxin derivative DX-8951 (Dxd) connected through an ADC linker [1].

Exatecan analog 36, an analog of Exatecan (DX-8951), is a common toxin component in ADC preparation (ADC Cytotoxin) and an inhibitor of DNA topoisomerase I (IC50=2.2 μM) [1].

Exatecan Intermediate 2 (compound B) is a precursor used in the synthesis of Exatecan (DX-8951), an anticancer agent classified among the camptothecin analogs. Exatecan operates by interacting with DNA to disrupt the proliferation and division of tumor cells, effectively inhibiting tumor growth. It is primarily employed in research targeting various cancers, including ovarian, lung, and breast cancer.

Exatecan Intermediate 6 serves as an intermediate in the synthesis of Exatecan (DX-8951), a DNA topoisomerase I inhibitor with an IC50 value of 2.2 μM (0.975 μg/mL), utilized in cancer research. Additionally, Exatecan Intermediate 6 is employed in the preparation of Antibody-Drug Conjugates (ADCs).

Exatecan Intermediate 7 is an intermediary in the production of Exatecan (DX-8951), a DNA topoisomerase I inhibitor with an IC50 value of 2.2 μM (0.975 μg/mL), utilized in cancer research. This intermediate is also employed in the synthesis of Antibody-Drug Conjugates (ADCs).

Exatecan Intermediate 5 serves as an intermediate in the synthesis of Exatecan (DX-8951), a DNA topoisomerase I (topoisomerase I) inhibitor with an IC50 of 2.2 μM (0.975 μg/mL), utilized in cancer research. This intermediate is also employed in the production of Antibody-Drug Conjugates (ADCs).

Exatecan Intermediate 2 hydrochloride (compound B) serves as an intermediary in the synthesis of Exatecan (DX-8951), a camptothecin analog and anticancer agent. This compound operates by interacting with DNA to disrupt the proliferation and division of tumor cells, thereby inhibiting tumor growth. It is primarily researched for its potential applications in treating various cancers including ovarian, lung, and breast cancer.